Eli Lilly (LLY) Q3 2026 Earnings Call Transcript
Company Participants
- Operator
- Mike Czapar - SVP of Investor Relations, Eli Lilly and Company
- Dave Ricks - Chair and CEO, Eli Lilly and Company
- Lucas Montarce - CFO, Eli Lilly and Company
- Dan Skovronsky - Chief Scientific and Product Officer, Eli Lilly and Company
- Chris Schott - Senior Analyst of US Diversified Biopharma, JPMorgan
- Geoff Meacham - Managing Director of Pharmaceuticals and Biotechnology, Citi
- Ilya Yuffa - President of Lilly USA and Global Customer Capabilities, Eli Lilly and Company
- Seamus Fernandez - Senior Analyst and Senior Managing Director, Guggenheim
- Carole Ho - President of Lilly Neuroscience, Eli Lilly and Company
- Evan Seigerman - Managing Director and Head of Healthcare Research, BMO Capital Markets
- Kerry Holford - Head of Global Pharmaceutical Equity Research, Berenberg
- Asad Haider - Head of the US Healthcare Business, Goldman Sachs
- Patrik Jonsson - President of Lilly International, Eli Lilly and Company
- Steve Scala - Managing Director of Health Care and Major Pharmaceuticals Research Analyst, TD Cowen
- Terence Flynn - Head of US Pharma and Biotech Research, Morgan Stanley
- Ken Custer - President of Lilly Cardiometabolic Health, Eli Lilly and Company
- Trung Huynh - Managing Director of Equity Research, RBC
- Akash Tewari - Global Head of Biopharmaceutical Research, Jefferies
- Umer Raffat - Senior Managing Director, Evercore
- Jake Van Naarden - President of Lilly Oncology and Head of Business Development, Eli Lilly and Company
- Carter Gould - Managing Director and Senior Analyst, Cantor
- Michael Yee - Global Head of Biotechnology Research and Managing Director and Senior Biotechnology and Pharma Analyst, UBS Securities
- Courtney Breen - Senior Analyst, Bernstein